Additionally, our exploratory objective will examine blood biomarkers that are mechanistically related to psilocybin and/or MDD including those involved with increased neurogenesis and neuroplasticity (BDNF), glial pathology (S100B), and systemic inflammation (CRP). Here, BDNF is linked to major depressive disorder.